|Author(s)/Faculty: Carmen A. Puliafito, MD, MBA; Pravin Dugel, MD; Peter K. Kaiser, MD|
|Release Date: 3/4/2016||Expiration Date: 3/3/2017|
|Credit Type: CME||Number of Credits: 0|
|Content Type: Lecture||Provider: |
|Intravitreal therapy with anti-VEGF agents has rapidly become the new standard of care in diabetic macular edema (DME), and is increasingly recognized as an effective means of managing the underlying diabetic retinopathy (DR). Furthermore, the renaissance of corticosteroid therapy in the form of intravitreal implants adds further valuable treatment options, and laser therapy remains an important and valuable tool in diabetic retinal disease. In this CME activity, the clinical evidence concerning the use of available treatment options for the management of diabetic retinal disease and the comparative data pertaining to the use of anti-VEGF therapy will be examined.